Fig. 1 · Structure

Documents & Downloads

Ganetespib (STA-9090)

Cat. No. A11402 CAS 888216-25-9

Hsp90 inhibitor

Ganetespib is a potent, synthetic, small molecule inhibitor of Hsp90, a chaperone protein that is essential to the function of certain other proteins that drive the growth, proliferation, and survival of many different types of cancer.

In Stock

Publications for Ganetespib

7 publications citing this product

  1. Dilay Karademir, .et al. , Med Oncol, 2023, Jul 11;40(8):234 PMID: 37432531
  2. Tung-Yun Wu, .et al. , J Adv Res, 2022, Jun 22;S2090-1232(22)00148-5 PMID: 35752438
  3. Aykut Ozgur, .et al. , J Chemother, 2021, Apr 2;1-10 PMID: 33794753
  4. Michael Heider, .et al. , Mol Cell, 2021, Mar 18;81(6):1170-1186 PMID: 33571422
  5. Kosinsky RL, .et al. , Cell Death Dis, 2019, Dec 4;10(12):911 PMID: 31801945
  6. Yamada-Kanazawa S, .et al. , Br J Dermatol, 2017, Aug;177(2):456-469 PMID: 28078663
  7. Hiroki Murano, .et al. , Plant Biotechnol Rep, 2017, 11:107-113

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Ganetespib (STA-9090) binds HSP90, as supported by competition with biotinylated geldanamycin in NCI-H1975 cell lysates. It reduced HSP90 capture at lower concentrations than 17-AAG in this assay; these comparison concentrations are not an IC50 or a binding constant. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
HSP90 (OSA 8 cells) 4 nM

Cellular Effect

Cell Line Activity Value Description Reference
A-375 IC50 15 nM Cytotoxicity against human A375 cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo luminescence assay [PMID: 26844689]
HCT-116 GI50 0.15 μM Antiproliferative activity against human HCT-116 cells measured after 48 hrs by SRB assay [PMID: 32683166]
HeLa IC50 11.65 nM Antiproliferative activity against human HeLa cells by MTT assay [PMID: 31839539]
NCI-H2228 IC50 13 nM Inhibition of E6a/b;A20 EML4-ALK (unknown origin) expressed in human NCI-H2228 cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo luminescence assay [PMID: 26844689]
NCI-H3122 IC50 10 nM Inhibition of E13;A20 EML4-ALK variant (unknown origin) expressed in human NCI-H3122 cells assessed as decrease in cell viability after 72 hrs by CellTiter-Glo luminescence assay [PMID: 26844689]
PC-3 IC50 9.3 nM Antiproliferative activity against human PC3 cells by MTT assay [PMID: 31839539]

Ganetespib (STA-9090) Research Summary

This section summarizes 2 in vitro studies and 2 in vivo studies of Ganetespib (STA-9090) from 2 published references. In vitro models include NCI-H1975 cell lysate as a source of HSP90.

Ganetespib (STA-9090) In Vitro Studies

Ganetespib sensitivity depended on cellular context: USP22 depletion increased the response of HCT116 and HCC1954 cells in a 48-hour crystal-violet experiment. This comparison does not establish a single potency value across tumor types. [2]

Competition with biotinylated geldanamycin for HSP90

Biochemical assay · NCI-H1975 (EGFR L858R/T790M) cell lysate as a source of HSP90 [1]

Ganetespib reduced capture of HSP90 by bead-bound biotinylated geldanamycin at lower concentrations than 17-AAG. This competition experiment supports HSP90 binding; it does not provide an equilibrium dissociation constant or an ATPase IC50.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Reduced HSP90 binding to biotinylated geldanamycinReported comparison concentrations, not IC50 Reduction reported at 0.11 µmol/L ganetespib; 1 µmol/L 17-AAG was required for a similar reduction.[1]

Literature-Reported Treatment Conditions

Treatment concentration
Ganetespib and 17-AAG concentration series, 0–1 µmol/L; DMSO at 0 µmol/L
Exposure duration
30 min drug preincubation followed by 1 h with biotin-GM beads, at 4 °C
Method
Competitive HSP90 capture followed by anti-HSP90 Western blot
Vehicle
DMSO control
Co-treatment
No combination treatment; 17-AAG was a separate comparator.
Reported limits
Replicate number and uncertainty for the qualitative blot are not specified in the adopted caption/results.
Methods and source locations

Compound reported in the paper: Ganetespib (STA-9090); Compound label in the paper: ganetespib

Findings apply to the named tested material and experimental model; they do not establish identity, purity or performance of a current A11402 lot.

Fig. 1A and caption; HSP90 binding assays; first Results subsection; Cell lines and drug treatments

Reduced HSP90 binding to biotinylated geldanamycin: Cell-lysate competition and HSP90 immunoblot — Fig. 1A, caption and first Results paragraph

USP22 depletion increases cellular sensitivity to ganetespib

Cell-based study · HCT116 colorectal carcinoma and HCC1954 mammary carcinoma cells; USP22-targeting siRNA versus non-targeting control siRNA [2]

After 48 h of ganetespib exposure, crystal-violet staining showed increased drug sensitivity in USP22-depleted cells relative to control-transfected cells in both models. This is a genetic-context comparison rather than a universal potency estimate.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Adherent cell staining after ganetespib treatmentQualitative concentration response USP22-depleted HCT116 and HCC1954 cells showed greater sensitivity than their non-targeting siRNA controls after 48 h.[2]

Literature-Reported Treatment Conditions

Treatment concentration
Increasing ganetespib concentrations in nM, with 0 nM controls (Fig. 4a); no fitted IC50 adopted
Exposure duration
Drug added 24 h after siRNA knockdown and continued for 48 h
Method
Cell exposure followed by crystal-violet staining
Vehicle
DMSO negative control
Co-treatment
Ganetespib tested with genetic USP22 depletion; no second drug
Reported limits
Fig. 4a does not state a replicate number. Seven-day confluence panels 4b–e are not used to assign a dose, duration or IC50 to this experiment.
Methods and source locations

Compound reported in the paper: Ganetespib (STA-9090); Compound label in the paper: ganetespib

Findings apply to the named tested material and experimental model; they do not establish identity, purity or performance of a current A11402 lot.

Fig. 4a and caption; Cell culture and siRNA-mediated knockdowns; Proliferation assays; Results: USP22 deficiency sensitizes CRC and breast cancer cells towards HSP90i

Adherent cell staining after ganetespib treatment: Crystal-violet staining; no numerical viability fraction or fitted IC50 inferred — Fig. 4a image and caption; corresponding Results paragraph

Ganetespib (STA-9090) In Vivo Studies

In NCI-H1975 xenografts, a single 125 mg/kg intravenous dose reduced EGFR staining at 24 hours and decreased proliferation while increasing apoptosis at 24–48 hours. Recovery of the proliferation and apoptosis readouts was evident at 72 hours, limiting claims of sustained activity from a single dose. [1]

At the tested 25 mg/kg intravenous regimen, ganetespib preferentially suppressed USP22-deficient HCT116 xenografts, whereas USP22-proficient tumors showed little growth response. Untreated USP22-deficient tumors grew faster, underscoring that the observed drug response depends on genotype and treatment conditions. [2]

Transient pharmacodynamic response in NCI-H1975 xenografts

Animal study · Female 7–8-week-old C.B-17 SCID mice bearing subcutaneous NCI-H1975 xenografts (EGFR L858R/T790M) [1]

A single intravenous dose reduced EGFR staining at 24 h, with reduced BrdU incorporation and increased TUNEL staining at 24–48 h. These proliferation/apoptosis effects showed recovery at 72 h. EGFR staining was not significantly decreased at 6 h.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor EGFR stainingQualitative direction Reduced at 24 h, but not significantly at 6 h.[1]
Tumor proliferation and apoptosisQualitative time course BrdU incorporation decreased and TUNEL staining increased at 24–48 h, with recovery evident at 72 h.[1]

Conditions shared by the study groups

Route
Intravenous
Frequency
Once
Treatment course
Single dose, followed for up to 72 h
Vehicle
10/18 DRD: 10% DMSO, 18% Cremophor RH40, 3.6% dextrose, 68.4% water
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Single-dose ganetespib
125 mg/kg
Vehicle-treated xenografts at the corresponding collection timesTransient EGFR/proliferation/apoptosis effects as described in Fig. 4; recovery of the latter effects at 72 h.[1]
Single-dose ganetespib
Model: NCI-H1975 xenografts in C.B-17 SCID mice
Reported limits: N = 8/group as captioned; exact time-point allocation unclear.
Methods and source locations

Compound reported in the paper: Ganetespib (STA-9090); Compound label in the paper: ganetespib

Findings apply to the named tested material and experimental model; they do not establish identity, purity or performance of a current A11402 lot.

Fig. 4A–B and caption; Xenograft immunohistochemistry and image analysis; Establishment and treatment of xenografts; corresponding Results paragraph

Tumor EGFR staining: EGFR immunohistochemistry; N = 8/group as captioned; error bars + SEM — Fig. 4A and corresponding Results paragraph

Tumor proliferation and apoptosis: Multicolor tumor-section imaging; N = 8/group as captioned; error bars + SEM — Fig. 4B and corresponding Results paragraph

Single-dose ganetespib · Fig. 4A–B and caption; dedicated xenograft IHC methods; general xenograft formulation methods

USP22-dependent response of HCT116 xenografts

Animal study · Immunodeficient SCID mice bearing HCT116 USP22+/+ and USP22−/− subcutaneous xenografts; the methods place the two genotypes in opposite flanks [2]

Ganetespib had little effect on USP22-proficient tumors but preferentially suppressed the more rapid growth of USP22-deficient tumors. Ki67 staining also decreased in treated USP22-deficient tumors. The authors report >70% growth impairment in the deficient tumors and a size 50% smaller than treated wild-type tumors.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Xenograft growth by USP22 genotypeAuthor-reported relative growth/size Little effect in USP22+/+ tumors; USP22−/− tumor growth impaired by more than 70%, with size 50% smaller than ganetespib-treated wild-type tumors (authors' text).[2]
Ki67-positive tumor cellsQualitative direction Ki67-positive cells decreased in ganetespib-treated USP22−/− tumors versus vehicle-treated USP22−/− tumors.[2]

Conditions shared by the study groups

Route
Intravenous
Frequency
Daily on three consecutive days, four-day break, then three further daily doses
Treatment course
Two three-day treatment blocks; tumors followed through day 23 in Fig. 5
Vehicle
10% DMSO (v/v), 20% Cremophor RH40 (v/v), 5% dextrose (w/v)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Ganetespib, both USP22 genotypes
25 mg/kg
Vehicle treatment within both USP22 genotypes; untreated USP22−/− tumors had accelerated growth.Little growth effect in wild-type tumors; preferential suppression of USP22-deficient tumors with reduced Ki67 staining.[2]
Ganetespib, both USP22 genotypes
Model: HCT116 USP22+/+ and USP22−/− xenografts in SCID mice
Reported limits: n = 6 per group as reported. No inference of independent animals from bilateral tumor number; sex/age/SCID substrain not stated in the adopted methods.
Methods and source locations

Compound reported in the paper: Ganetespib (STA-9090); Compound label in the paper: ganetespib

Findings apply to the named tested material and experimental model; they do not establish identity, purity or performance of a current A11402 lot.

Fig. 5a–e and caption; Xenograft experiments; Statistical analyses; Results: USP22-deficient tumor cells display increased sensitivity to HSP90 inhibition

Xenograft growth by USP22 genotype: Tumor monitoring; n = 6 per group as reported; mean ± SEM, Student’s t-test in Fig. 5a–b — Fig. 5a–c and Results: USP22-deficient tumor cells display increased sensitivity to HSP90 inhibition

Ki67-positive tumor cells: Ki67 immunohistochemistry; mean ± SEM, one-way ANOVA — Fig. 5d–e and caption

Ganetespib, both USP22 genotypes · Xenograft experiments; Fig. 5a–e and caption; corresponding Results

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 888216-25-9
Applications Hsp90 inhibitor
Formula C20H20N4O3
Molecular Weight 364.4
Synonyms STA9090
SMILES
CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3c(ccn3C)c2)c(O)cc1O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 37 mg/mL (101.53 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
10 mg/mL
Vehicle
5% DMSO+45% PEG 300+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Ganetespib (STA-9090) Research References

  1. [1] Shimamura T, Perera SA, Foley KP, et al. Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2012). PMID: 22806877 DOI: 10.1158/1078-0432.ccr-11-2967 Source material
  2. [2] Kosinsky RL, Helms M, Zerche M, et al. USP22-dependent HSP90AB1 expression promotes resistance to HSP90 inhibition in mammary and colorectal cancer. Cell death & disease (2019). PMID: 31801945 DOI: 10.1038/s41419-019-2141-9 Source material

Publications

7 publications citing this product

  1. Dilay Karademir, .et al. , Med Oncol, 2023, Jul 11;40(8):234 PMID: 37432531
  2. Tung-Yun Wu, .et al. , J Adv Res, 2022, Jun 22;S2090-1232(22)00148-5 PMID: 35752438
  3. Aykut Ozgur, .et al. , J Chemother, 2021, Apr 2;1-10 PMID: 33794753
  4. Michael Heider, .et al. , Mol Cell, 2021, Mar 18;81(6):1170-1186 PMID: 33571422
  5. Kosinsky RL, .et al. , Cell Death Dis, 2019, Dec 4;10(12):911 PMID: 31801945
  6. Yamada-Kanazawa S, .et al. , Br J Dermatol, 2017, Aug;177(2):456-469 PMID: 28078663
  7. Hiroki Murano, .et al. , Plant Biotechnol Rep, 2017, 11:107-113

Added to your cart

View Cart Checkout
Loading...